Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SSTR1 | P30872 | 1/20 | 0.45 |
| ▸ | SSTR2 | P30874 | 1/20 | 0.45 |
| ▸ | SSTR4 | P31391 | 1/20 | 0.45 |
| ▸ | SSTR3 | P32745 | 1/20 | 0.45 |
| ▸ | SSTR5 | P35346 | 1/20 | 0.45 |
| ▸ | HTR1A | P08908 | 1/20 | 0.42 |
| ▸ | PTPN1 | P18031 | 9/20 | 0.42 |
| ▸ | PTPN2 | P17706 | 4/20 | 0.42 |
| ▸ | CDC25B | P30305 | 6/20 | 0.42 |
| ▸ | PTPN11 | Q06124 | 3/20 | 0.40 |
| ▸ | PTPN6 | P29350 | 2/20 | 0.40 |
| ▸ | TACR2 | P21452 | 1/20 | 0.40 |
| ▸ | GJB2 | P29033 | 1/20 | 0.40 |
| ▸ | NT5E | P21589 | 1/20 | 0.40 |
| ▸ | MAOB | P27338 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7217538 | 0.90 | SSTR1 (0.44) | SSTR1SSTR2SSTR4SSTR3SSTR5 | |
| SCHEMBL5271619 | 0.85 | SSTR1 (0.44) | SSTR1SSTR2SSTR4SSTR3SSTR5 | |
| SCHEMBL674921 | 0.84 | SSTR1 (0.50) | SSTR1SSTR2SSTR4SSTR3SSTR5 | |
| SCHEMBL28411979 | 0.83 | SSTR1 (0.47) | SSTR1SSTR2SSTR4SSTR3SSTR5 | |
| SCHEMBL2130834 | 0.81 | SSTR1 (0.41) | SSTR1SSTR2SSTR4SSTR3SSTR5 | |
| SCHEMBL4398922 | 0.80 | SSTR1 (0.45) | SSTR1SSTR2SSTR4SSTR3SSTR5 | |
| SCHEMBL7222328 | 0.79 | SSTR1 (0.48) | SSTR1SSTR2SSTR4SSTR3SSTR5 | |
| SCHEMBL2969611 | 0.79 | SSTR1 (0.39) | SSTR1SSTR2SSTR4SSTR3SSTR5 | |
| SCHEMBL14795427 | 0.79 | PTPN1 (0.46) | SSTR1SSTR2SSTR4SSTR3SSTR5 | |
| SCHEMBL2574835 | 0.79 | PTPN1 (0.42) | SSTR1SSTR2SSTR4SSTR3SSTR5 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8058245-B2 | Fused heterocycle derivative, medicinal composition containing the same, and medicinal use thereof | KISSEI PHARMACEUTICAL CO., LTD. (JP) | 2011-11-15 | — | — | US | disclosed |
| US-20070197450-A1 | Fused heterocycle derivative, medicinal composition containing the same, and medicinal use thereof | KISSEI PHARMACEUTICAL CO., LTD. | 2007-08-23 | — | — | US | disclosed |
| EP-1721904-A1 | FUSED HETEROCYCLE DERIVATIVE, MEDICINAL COMPOSITION CONTAINING THE SAME, AND MEDICINAL USE THEREOF | Kissei Pharmaceutical Co., Ltd. (JP) | 2006-11-15 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070197450-A1 | Fused heterocycle derivative, medicinal composition containing the same, and medicinal use thereof | SLC5A1, SLC5A2, GPR119 | SSTR1 643/4885SSTR2 622/4885SSTR4 689/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.